Pharmaceuticals, Biotechnology and Life Sciences
IDMC has recommended that all three doses continue to be tested in the ongoing Phase 2b trial for BGS-649, an inhibitor for obese men with hypogonadotropic hypoganadism.
Belgian-headquartered biopharmaceutical company TiGenix has received positive feedback from the U.S. Food and Drug Administration (FDA) for its improved phase III trial for the treatment of complex perianal fistulas in Crohn’s disease patients.
Biohaven Pharmaceutical, a privately-held, clinical stage biopharmaceutical company focused neurological diseases, has completed the second tranche of its previously disclosed $80 million private financing, and has welcomed new board members, which saw one board member step down.
Lexicon Pharmaceuticals’ Xermelo was recently approved with orphan status by the Food and Drug Administration (FDA) and Diplomat, the USA largest independent specialty pharmacy, will fill prescriptions for it, as it has been selected to the limited-distribution panel of the drug.
Patients with eosinophilic inflammation that were treated with GSK’s mepolizumab Nucala as addition to the standard care, reached improvements in health and lung function compared to patients treated with placebo added to the standard care.
Herantis Pharma clinical study with the company’s innovative gene therapy investigational product Lymfactin for the treatment of secondary lymphedema has advanced to highest planned dose level owing to good reported safety.
Futura Medical has filed a new formulation patent for its topical gel for the treatment of erectile dysfunction, with the UK Intellectual Property Office in connection with MED2002.
AB Science has recruited 350 patients for the phase 3 study (AB07015) in severe persistent asthma uncontrolled by oral corticosteroids, for which the final results will be available at the end of 2017.
Amryt is on track to begin the phase 3 trial at the end of March for its new skin healing treatment in an orphan disease, with regulatory authority discussions now completed with Food and Drug Administration (FDA) and European Medicines Agency (EMA) and the design of the clinical trial established.
Abzena, a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, has reported that one of the ‘Abzena inside’ Composite Human Antibody products for the treatment of neurodegenerative conditions has moved to Phase II clinical trial.